About us
“Future Biopharma KSA is a rapidly expanding pharmaceutical company based in Jeddah, Saudi Arabia. A proud subsidiary of Nahran, a company specializing in general construction and cladding since its establishment in 2013, Nahran also encompasses divisions dedicated to medical glass and overall medical services.”
“Initiating our venture with an initial investment of 500,000 SR, we have grown exponentially, achieving a market value of 100 million SR. In addition to this success, our fixed assets and supply contracts are estimated at approximately 600 million SR. Our strategic partnerships, including those with the Saudi National Bank, Al-Rajhi Bank, and Aramco, have played a pivotal role in our journey. ”
“Aligned with the 2030 Saudi Vision for economic transformation and the advancement of local healthcare and pharmaceutical industries, Nahran collaborates closely with partners and investors to be a key player in this transformation. ”
“As a fast-growing pharmaceutical company, Future Biopharma KSA boasts regional capabilities in Contract Development and Manufacturing Organization (CDMO), warehouse management, and efficient distribution facilities. Our collaborations extend globally, establishing fruitful partnerships with several international pharmaceutical companies. .”
“Presently, Future Biopharma KSA is making significant contributions in the biological products sector, specializing in blood derivatives, vaccines, and Biosimilars, thereby playing a vital role in advancing healthcare and pharmaceuticals. ”
Saudi Arabia strategic plan
Increasing local pharmaceutical Manufacturers.
Offering financial assistance to local Pharma manufacturers.
Offering all support for biopharmaceutical localization.
Protecting local brands against branded generics.
WHY US
Future Biopharma KSA strives to develop affordable biopharmaceutical care solutions and enable Saudi pharmaceutical companies to be players in the global pharmaceutical market.
Continuous develop and upgrade the Pharmaceutical industry into world-class standards that implements cGMP, GCP, and GLP standards.
Continuous advice and play a consultative role in the Saudi healthcare system by working closely with the SFDA and the Ministry of Health in Saudi Arabia.
Facilitate the transfer of related technology and know-how.
Improving patients' lives, Access to affordable medicines ensuring the sustainability of healthcare Systems.
Being a leading company for Biosimilar and niche therapeutic product.
Being a production hub for Saudi Arabia & GCC, the Middle East and North Africa
First phase
Strategic collaboration for sourcing biopharmaceutical products with complete technology transfer.
Secondary packaging for all dosage forms including.
temperature-controlled goods such as Biosimilar, MAbs, Vaccines, Hormones and blood derivatives.
Second phase
Primary filling for all dosage forms, bulk products or APIs under cGMP guidelines . Dedicated lines for Biosimilar, MAbs, Vaccines, Hormones and blood derivatives.
Third phase
Future Biopharma KSA will provide end-to-end solutions for development, technology transfer and manufacture of Biosimilar DS to cater the need. Future Biopharma KSA will provide full turn-key technology transfer-based process adaptation to meet cGMP requirements. Include cell line development, upstream, downstream and Q.C to full cGMP production aiming for higher quality and cost efficiency.